Greater Glasgow and Clyde Medicines
Key to symbols The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP The medicine should only be used and prescribed by a specialist Indicates the preferred choice within a class or group of medicines
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
10.2. Drugs used in neuromuscular disorders

10.2.3. Other neuromuscular drugs

Total Formulary
Specialist Only
ATALUREN (Translarma) (oral suspension)

Restrictions:

Restricted to specialist use only.

Prescribing Notes:

Ataluren may be prescribed within the ultra-orphan pathway while further evidence on its effectiveness is generated.  In 2025, the SMC will evaluate the medicine for routine use in NHS Scotland.  This medicine is part of the national Ultra-Orphan Risk Share Scheme.

BNF Link

Specialist Only
MEXILETINE (Namuscla) (capsules)

Restrictions:

Restricted to specialist use for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders.

Prescribing Notes:

For other indications please see section 2.3.2

BNF Link

Specialist Only
NUSINERSEN (injection)

Restrictions:

Restricted to specialist use only for the treatment of type II and III 5q spinal muscular atrophy (SMA). 

Prescribing Notes:

  • This therapy is available via the Scottish Government Ultra-orphan pathway with reassessment by SMC following 3 years of data collection. Appropriate paperwork needs completing before prescribing to ensure registration on the national risk sharing scheme.
  • SMA type I is already accepted for use by SMC and is available in the GGC Paediatric Formulary.

BNF Link

Specialist Only
RISDIPLAM (oral solution)

Restrictions:

Restricted to specialist use only in the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA type 1, type 2 or type 3 or with one to four SMN2 [survival of motor neuron 2] copies.

Prescribing Notes:

Available via the Ultra Orphan Pathway with reassessment by SMC following 3 years of data collection. Appropriate paperwork needs completing before prescribing to ensure registration on the national risk sharing scheme.

BNF Link